e-learning
resources
Madrid 2019
Sunday, 29.09.2019
The world of idiopathic pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Factors affecting the compliance to antifibrotic treatment in patients with interstitial pulmonary fibrosis
Z. Bingol (Istanbul, Turkey), S. Oguz (Istanbul, Turkey), Z. Kilicaslan (Istanbul, Turkey), E. Kiyan (Istanbul, Turkey), G. Okumus (Istanbul, Turkey)
Source:
International Congress 2019 – The world of idiopathic pulmonary fibrosis
Session:
The world of idiopathic pulmonary fibrosis
Session type:
Poster Discussion
Number:
1726
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Z. Bingol (Istanbul, Turkey), S. Oguz (Istanbul, Turkey), Z. Kilicaslan (Istanbul, Turkey), E. Kiyan (Istanbul, Turkey), G. Okumus (Istanbul, Turkey). Factors affecting the compliance to antifibrotic treatment in patients with interstitial pulmonary fibrosis. 1726
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF treatment II
Year: 2016
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
Source: Eur Respir J 2016; 48: 843-851
Year: 2016
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
The effectiveness of pulmonary rehabilitation in patients diagnosed with interstitial pulmonary fibrosis
Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care
Year: 2020
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019
Year: 2019
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Source: Eur Respir Rev 2012; 21: 161-167
Year: 2012
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence?
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Clinical characteristics, haemodynamics, and survival in patients with combined pulmonary fibrosis and emphysema and associated pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary vascular medicine
Year: 2008
LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases
Year: 2015
Effect of baseline statin use on benefit of nintedanib
Source: International Congress 2016 – IPF treatment II
Year: 2016
Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 342s
Year: 2002
Safety of antifibrotic drugs in idiopathic pulmonary fibrosis patients awaiting lung transplantation
Source: International Congress 2018 – Moving lung transplantation forward
Year: 2018
Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis
Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019
Year: 2019
Comparison of clinical characteristics and prognostic factors between combined pulmonary fibrosis and emphysema/UIP versus non-UIP
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021
Year: 2021
Negative outcome of prednisone in possible idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF clinical
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept